Hangzhou, China

Liyong Wu

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Hangzhou Huibo Science and Technology Co., Ltd. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Liyong Wu. Retrieved from https://idiyas.com/inventor/liyong-wu-szrpy04e

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Liyong Wu: Innovator in Cyclic Peptide Technology

Introduction

Liyong Wu is a prominent inventor based in Hangzhou, China. He has made significant contributions to the field of cyclic peptides, showcasing his expertise through innovative research and development.

Latest Patents

Liyong Wu holds a patent for a "Cyclic Peptide and Preparation Method and Use Thereof." This patent highlights his work in developing new methods and applications for cyclic peptides, which are essential in various biomedical fields.

Career Highlights

Wu is associated with Hangzhou Huibo Science and Technology Co., Ltd., where he continues to advance his research. His dedication to innovation has positioned him as a key figure in his company and the broader scientific community.

Collaborations

Liyong Wu collaborates with talented individuals such as Gang Wu and Yunyu Lu. These partnerships enhance his research capabilities and contribute to the success of their projects.

Conclusion

Liyong Wu's work in cyclic peptide technology exemplifies the spirit of innovation. His contributions are paving the way for advancements in the field, and his collaborations further strengthen the impact of his research.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…